Last reviewed · How we verify
NCT04588129
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
Phase 1 trial testing LB-102 in Schizophrenia in 16 participants. Completed in 15 November 2021.
17 September 2021
Quick facts
| Lead sponsor | LB Pharmaceuticals Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 16 |
| Start date | 5 January 2021 |
| Primary completion | 17 September 2021 |
| Estimated completion | 15 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- LB-102 — full drug profile →
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
LB Pharmaceuticals Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
ACNP 60<sup>th</sup> Annual Meeting: Poster Abstracts P276 - P550.
· 2021 · cited 3× · PMID 34857905 · DOI 10.1038/s41386-021-01237-6 -
PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.
Wong DF, Chand GB, Caito N, Eramo A, et al · · 2024 · cited 1× · PMID 39414986 · DOI 10.1038/s41386-024-01951-x
Verify or expand the search:
- PubMed search for NCT04588129
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LB-102
Trials testing the same drug.
- NCT06179108 — Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophreni · Phase 2 · completed
- NCT04187560 — Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults · Phase 1 · completed
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other LB Pharmaceuticals Inc. trials
Trials by the same sponsor.
- NCT06179108 — Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophreni · Phase 2 · completed
- NCT04187560 — Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04588129 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LB Pharmaceuticals Inc.
- Last refreshed: 4 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04588129.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing